Blocking GPR35 signaling also reduces the secretion of angiogenic factors, including vascular endothelial growth factor (VEGF) and CXCL1, thereby inhibiting tumor angiogenesis and tumor cell proliferation (30) (Figure 1). This evidence concerns the gene CXCL1 and neoplasm.